Identification of selective Lyn inhibitors from the chemical databases through integrated molecular modelling approaches

References

• E. Ingley, Functions of the Lyn tyrosine kinase in health and disease, Cell. Commun. Signal. 10 (2012), pp. 21–31. doi:10.1186/1478-811X-10-21.
   PubMed Web of Science ®Google Scholar
• G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam, The protein kinase complement of the human genome, Science 298 (2002), pp. 1912–1934. doi:10.1126/science.1075762.
   PubMed Web of Science ®Google Scholar
• S.J. Parsons and J.T. Parsons, Src family kinases, key regulators of signal transduction, Oncogene 23 (2004), pp. 7906–7909. doi:10.1038/sj.onc.1208160.
   PubMed Web of Science ®Google Scholar
• E. Ingley, Src family kinases: Regulation of their activities, levels and identification of new pathways, Biochim. Biophys. Acta 1784 (2008), pp. 56–65. doi:10.1016/j.bbapap.2007.08.012.
   PubMed Web of Science ®Google Scholar
• H. Pham, C. Birtolo, C. Chheda, W. Yang, M.D. Rodriguez, S.T. Liu, G. Gugliotta, M.S. Lewis, V. Cirulli, S.J. Pandol, and A. Ptasznik, Essential role of Lyn in fibrosis, Front. Physiol. 7 (2016), pp. 1–11. doi:10.3389/fphys.2016.00387.
   PubMed Web of Science ®Google Scholar
• E.J. Brodie, S. Infantino, M.S.Y. Low, and D.M. Tarlinton, Lyn, lupus, and (B) lymphocytes, a lesson on the critical balance of kinase signaling in immunity, Front. Immunol. 9 (2018), pp. 401–410. doi:10.3389/fimmu.2018.00401.
   PubMed Web of Science ®Google Scholar
• K. Kasahara, Y. Nakayama, K. Ikeda, Y. Fukushima, D. Matsuda, S. Horimoto, and N. Yamaguchi, Trafficking of Lyn through the golgi caveolin involves the charged residues on alphaE and alphaI helices in the kinase domain, J. Cell. Biol. 165 (2004), pp. 641–652. doi:10.1083/jcb.200403011.
   PubMed Web of Science ®Google Scholar
• M.L. Dykstra, A. Cherukuri, and S.K. Pierce, Floating the raft hypothesis for immune receptors: Access to rafts controls receptor signaling and trafficking, Traffic 2 (2001), pp. 160–166. doi:10.1034/j.1600-0854.2001.020302.x.
   PubMed Web of Science ®Google Scholar
• T. Hayashi, H. Umemori, M. Mishina, and T. Yamamoto, The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn, Nature 397 (1999), pp. 72–76. doi:10.1038/16269.
   PubMed Web of Science ®Google Scholar
• A. Hirao, X.L. Huang, T. Suda, and N. Yamaguchi, Overexpression of C-terminal Src kinase homologous kinase suppresses activation of Lyn tyrosine kinase required for VLA5-mediated Dami cell spreading, J. Biol. Chem. 273 (1998), pp. 10004–10010. doi:10.1074/jbc.273.16.10004.
   PubMed Web of Science ®Google Scholar
• H.M. Dingerdissen, J. Torcivia-Rodriguez, Y. Hu, T.C. Chang, R. Mazumder, and R. Kahsay, BioMuta and BioXpress: Mutation and expression knowledgebases for cancer biomarker discovery, Nucleic Acids Res. 46 (2018), pp. D1128–D1136. doi:10.1093/nar/gkx907.
   PubMed Web of Science ®Google Scholar
• E. Rupniewska, R. Roy, F.A. Mauri, X. Liu, M. Kaliszczak, G. Bellezza, L. Cagini, M. Barbareschi, S. Ferrero, A.M. Tommasi, E. Aboagye, M.J. Seckl, and O.E. Pardo, Targeting autophagy sensitises lung cancer cells to Src family kinase inhibitors, Oncotarget 9 (2018), pp. 27346–27362. doi:10.18632/oncotarget.25213.
   PubMedGoogle Scholar
• A.K. Roseweir, T. Qayyum, Z. Lim, R. Hammond, A.I. MacDonald, S. Fraser, G.M. Oades, M. Aitchison, R.J. Jones, and J. Edwards, Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients, BMC Cancer 16 (2016), pp. 1–10. doi:10.1186/s12885-016-2254-9.
   Web of Science ®Google Scholar
• D.R. Croucher, F. Hochgrafe, L. Zhang, L. Liu, R.J. Lyons, D. Rickwood, C.M. Tactacan, B.C. Browne, N. Ali, H. Chan, R. Shearer, D. Gallego-Ortega, D.N. Saunders, A. Swarbrick, and R.J. Daly, Involvement of Lyn and the atypical kinase SgK269/PEAK1 in a basal breast cancer signaling pathway, Cancer Res. 73 (2013), pp. 1969–1980. doi:10.1158/0008-5472.CAN-12-1472.
   PubMed Web of Science ®Google Scholar
• B. Elsberger, R. Fullerton, S. Zino, F. Jordan, T.J. Mitchell, V.G. Brunton, E.A. Mallon, P.G. Shiels, and J. Edwards, Breast cancer patients’ clinical outcome measures are associated with Src kinase family member expression, Br. J. Cancer 103 (2010), pp. 899–909. doi:10.1038/sj.bjc.6605829.
   PubMed Web of Science ®Google Scholar
• N.K. Williams, I.S. Lucet, S.P. Klinken, E. Ingley, and J. Rossjohn, Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state, J. Biol. Chem. 284 (2009), pp. 284–291. doi:10.1074/jbc.M807850200.
   PubMed Web of Science ®Google Scholar
• S. Berndt, V.V. Gurevich, and T.M. Iverson, Crystal structure of the SH3 domain of human Lyn non-receptor tyrosine kinase, PLoS One 14 (2019), pp. e0215140. doi:10.1371/journal.pone.0215140.
   PubMed Web of Science ®Google Scholar
• C. Dos Santos, C. Demur, V. Bardet, N. Prade-Houdellier, B. Payrastre, and C. Recher, A critical role for Lyn in acute myeloid leukemia, Blood 111 (2008), pp. 2269–2279. doi:10.1182/blood-2007-04-082099.
   PubMed Web of Science ®Google Scholar
• A.L. Samuels, S.P. Klinken, and E. Ingley, Liar, a novel Lyn-binding nuclear/cytoplasmic shuttling protein that influences erythropoietin-induced differentiation, Blood 113 (2009), pp. 3845–3856. doi:10.1182/blood-2008-04-153452.
   PubMed Web of Science ®Google Scholar
• K. Borzęcka-Solarz, J. Dembińska, A. Hromada-Judycka, G. Traczyk, A. Ciesielska, E. Ziemlińska, A. Świątkowska, and K. Kwiatkowska, Association of Lyn kinase with membrane rafts determines its negative influence on LPS-induced signaling, Mol. Biol. Cell 28 (2017), pp. 1147–1159. doi:10.1091/mbc.e16-09-0632.
   PubMed Web of Science ®Google Scholar
• P. Sutton, J.A. Borgia, P. Bonomi, and J.M.D. Plate, Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells, Mol. Cancer 12 (2013), pp. 76. doi:10.1186/1476-4598-12-76.
   PubMed Web of Science ®Google Scholar
• G. Tornillo, C. Knowlson, H. Kendrick, J. Cooke, H. Mirza, I. Aurrekoetxea-Rodriguez, M.D.M. Vivanco, N.E. Buckley, A. Grigoriadis, and M.J. Smalley, Dual mechanisms of Lyn kinase dysregulation drive aggressive behavior in breast cancer cells, Cell Rep. 25 (2018), pp. 3674–3692 e10. doi:10.1016/j.celrep.2018.11.103.
   PubMed Web of Science ®Google Scholar
• L.J. Schwarz, E.M. Fox, J.M. Balko, J.T. Garrett, M.G. Kuba, M.V. Estrada, A.M. González-Angulo, G.B. Mills, M. Red-Brewer, I.A. Mayer, V. Abramson, M. Rizzo, M.C. Kelley, I.M. Meszoely, and C.L. Arteaga, LYN-activating mutations mediate antiestrogen resistance in estrogen receptor–positive breast cancer, J. Clin. Invest. 124 (2014), pp. 5490–5502. doi:10.1172/JCI72573.
   PubMed Web of Science ®Google Scholar
• S. Chakraborty, T. Inukai, L. Fang, M. Golkowski, and D.J. Maly, Targeting dynamic ATP-binding site features allows discrimination between highly homologous protein kinases, ACS Chem. Biol. 14 (2019), pp. 1249–1259. doi:10.1021/acschembio.9b00214.
   PubMed Web of Science ®Google Scholar
• K.R. Brandvold, M.E. Steffey, C.C. Fox, and M.B. Soellner, Development of a highly selective c-Src kinase inhibitor, ACS Chem. Biol. 7 (2012), pp. 1393–1398. doi:10.1021/cb300172e.
   PubMed Web of Science ®Google Scholar
• M.I. Davis, J.P. Hunt, S. Herrgard, P. Ciceri, L.M. Wodicka, G. Pallares, M. Hocker, D.K. Treiber, and P.P. Zarrinkar, Comprehensive analysis of kinase inhibitor selectivity, Nat. Biotechnol. 29 (2011), pp. 1046–1051. doi:10.1038/nbt.1990.
   PubMed Web of Science ®Google Scholar
• S. Genheden and U. Ryde, The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities, Expert. Opin. Drug Discov. 10 (2015), pp. 449–461. doi:10.1517/17460441.2015.1032936.
   PubMed Web of Science ®Google Scholar
• ASINEX database, ASINEX Corporation, Winston-Salem, USA, 2019.
   Google Scholar
• P. de Matos, R. Alcantara, A. Dekker, M. Ennis, J. Hastings, K. Haug, I. Spiteri, S. Turner, and C. Steinbeck, Chemical entities of biological interest: An update, Nucleic Acids Res. 38 (2010), pp. D249–D254. doi:10.1093/nar/gkp886.
   PubMed Web of Science ®Google Scholar
• Virtual screening workflow, Schrödinger, LLC, New York, 2018; software available at https://www.schrodinger.com/.
   Google Scholar
• Discovery Studio, Dassault Systèmes BIOVIA, San Diego, 2016; software available at https://www.3ds.com/products-services/biovia/.
   Google Scholar
• N. Miyano, T. Kinoshita, R. Nakai, Y. Kirii, K. Yokota, and T. Tada, Structural basis for the inhibitor recognition of human Lyn kinase domain, Bioorg. Med. Chem. Lett. 19 (2009), pp. 6557–6560. doi:10.1016/j.bmcl.2009.10.038.
   PubMed Web of Science ®Google Scholar
• LigPrep, Schrödinger, LLC, New York, 2018; software available at https://www.schrodinger.com/.
   Google Scholar
• J.C. Shelley, A. Cholleti, L.L. Frye, J.R. Greenwood, M.R. Timlin, and M. Uchimaya, Epik: A software program for pKa prediction and protonation state generation for drug-like molecules, J. Comput. Aided. Mol. Des. 21 (2007), pp. 681–691. doi:10.1007/s10822-007-9133-z.
   PubMed Web of Science ®Google Scholar
• H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig, I.N. Shindyalov, and P.E. Bourne, The protein data bank, Nucleic Acids Res. 28 (2000), pp. 235–242. doi:10.1093/nar/28.1.235.
   PubMed Web of Science ®Google Scholar
• Protein Preparation Wizard, Schrödinger, LLC, New York, 2018; software available at https://www.schrodinger.com/.
   Google Scholar
• G. Madhavi Sastry, M. Adzhigirey, T. Day, R. Annabhimoju, and W. Sherman, Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments, J. Comput. Aided Mol. Des. 27 (2013), pp. 221–234. doi:10.1007/s10822-013-9644-8.
   PubMed Web of Science ®Google Scholar
• E. Harder, W. Damm, J. Maple, C. Wu, M. Reboul, J.Y. Xiang, L. Wang, D. Lupyan, M.K. Dahlgren, J.L. Knight, J.W. Kaus, D.S. Cerutti, G. Krilov, W.L. Jorgensen, R. Abel, and R.A. Friesner, OPLS3: A force field providing broad coverage of drug-like small molecules and proteins, J. Chem. Theory. Comput. 12 (2016), pp. 281–296. doi:10.1021/acs.jctc.5b00864.
   PubMed Web of Science ®Google Scholar
• R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz, M.P. Repasky, E.H. Knoll, M. Shelley, J.K. Perry, D.E. Shaw, P. Francis, and P.S. Shenkin, Glide: A new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy, J. Med. Chem. 47 (2004), pp. 1739–1749. doi:10.1021/jm0306430.
   PubMed Web of Science ®Google Scholar
• B. Wright, K.A. Watson, L.J. McGuffin, J.A. Lovegrove, and J.M. Gibbins, GRID and docking analyses reveal a molecular basis for flavonoid inhibition of Src family kinase activity, J. Nutr. Biochem. 26 (2015), pp. 1156–1165. doi:10.1016/j.jnutbio.2015.05.004.
   PubMed Web of Science ®Google Scholar
• QikProp, Schrödinger, LLC, New York, 2018; software available at https://www.schrodinger.com/.
   Google Scholar
• R. Kristam, V.J. Gillet, R.A. Lewis, and D. Thorner, Comparison of conformational analysis techniques to generate pharmacophore hypotheses using catalyst, J. Chem. Inf. Model. 45 (2005), pp. 461–476. doi:10.1021/ci049731z.
   PubMed Web of Science ®Google Scholar
• A. Smellie, S.L. Teig, and P. Towbin, Poling: Promoting conformational variation, J. Comp. Chem. 16 (1995), pp. 171–187. doi:10.1002/jcc.540160205.
   Web of Science ®Google Scholar
• A. Daina, O. Michielin, and V. Zoete, SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Sci. Rep. 7 (2017), pp. 42717. doi:10.1038/srep42717.
   PubMed Web of Science ®Google Scholar
• C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv. Rev. 46 (2001), pp. 3–26. doi:10.1016/S0169-409X(00)00129-0.
   PubMed Web of Science ®Google Scholar
• D.F. Veber, S.R. Johnson, H.Y. Cheng, B.R. Smith, K.W. Ward, and K.D. Kopple, Molecular properties that influence the oral bioavailability of drug candidates, J. Med. Chem. 45 (2002), pp. 2615–2623. doi:10.1021/jm020017n.
   PubMed Web of Science ®Google Scholar
• M. De Vrieze, P. Janssens, R. Szucs, J. Van der Eycken, and F. Lynen, In vitro prediction of human intestinal absorption and blood-brain barrier partitioning: Development of a lipid analog for micellar liquid chromatography, Anal. Bioanal. Chem. 407 (2015), pp. 7453–7466. doi:10.1007/s00216-015-8911-z.
   PubMed Web of Science ®Google Scholar
• V. Zoete, M.A. Cuendet, A. Grosdidier, and O. Michielin, SwissParam: A fast force field generation tool for small organic molecules, J. Comput. Chem. 32 (2011), pp. 235923–235968. doi:10.1002/jcc.21816.
   Web of Science ®Google Scholar
• J. Huang, S. Rauscher, G. Nawrocki, T. Ran, M. Feig, B.L. de Groot, H. Grubmuller, and A.D. MacKerell Jr., CHARMM36m: An improved force field for folded and intrinsically disordered proteins, Nat. Meth. 14 (2017), pp. 71–73. doi:10.1038/nmeth.4067.
   PubMed Web of Science ®Google Scholar
• P. Mark and L. Nilsson, Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K, Phys. Chem. A 105 (2001), pp. 9954–9960. doi:10.1021/jp003020w.
   Web of Science ®Google Scholar
• R. Kumari, R. Kumar, Open Source Drug Discovery, and A. Lynn, g_mmpbsa – A GROMACS tool for high-throughput MM-PBSA calculations, J. Chem. Inf. Model. 54 (2014), pp. 1951–1962. doi:10.1021/ci500020m
   PubMed Web of Science ®Google Scholar
• T. Zhu, S. Cao, P.C. Su, R. Patel, D. Shah, H.B. Chokshi, R. Szukala, M.E. Johnson, and K.E. Hevener, Hit identification and optimization in virtual screening: Practical recommendations based on a critical literature analysis, J. Med. Chem. 56 (2013), pp. 6560–6572. doi:10.1021/jm301916b.
   PubMed Web of Science ®Google Scholar
• Q. Li and S. Shah, Structure-based virtual screening, Meth. Mol. Biol. 1558 (2017), pp. 111–124.
   PubMedGoogle Scholar
• M.A. Al-Sha’er and M.O. Taha, Application of docking-based comparative intermolecular contacts analysis to validate Hsp90alpha docking studies and subsequent in silico screening for inhibitors, J. Mol. Model. 18 (2012), pp. 4843–4863. doi:10.1007/s00894-012-1479-z.
   PubMed Web of Science ®Google Scholar
• S. Salentin, S. Schreiber, V.J. Haupt, M.F. Adasme, and M. Schroeder, PLIP: Fully automated protein-ligand interaction profiler, Nucleic Acids Res. 43 (2015), pp. W443–W447. doi:10.1093/nar/gkv315.
   PubMed Web of Science ®Google Scholar
• A.K. Ghose, V.N. Viswanadhan, and J.J. Wendoloski, A knowledge-based approach in Designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases, J. Comb. Chem. 1 (1999), pp. 55–68. doi:10.1021/cc9800071.
   PubMed Web of Science ®Google Scholar
• A.L. Hopkins, C.R. Groom, and A. Alex, Ligand efficiency: A useful metric for lead selection, Drug. Discov. Today 9 (2004), pp. 430–431. doi:10.1016/S1359-6446(04)03069-7.
   PubMed Web of Science ®Google Scholar
• C.H. Reynolds, S.D. Bembenek, and B.A. Tounge, The role of molecular size in ligand efficiency, Bioorg. Med. Chem. Lett. 17 (2007), pp. 4258–4261. doi:10.1016/j.bmcl.2007.05.038.
   PubMed Web of Science ®Google Scholar
• X. Xue, G. Bao, H.Q. Zhang, N.Y. Zhao, Y. Sun, Y. Zhang, and X.L. Wang, An application of fit quality to screen MDM2/p53 protein-protein interaction inhibitors, Molecules 23 (2018), pp. 3174. doi:10.3390/molecules23123174.
   Web of Science ®Google Scholar
• G.M. Keseru and G.M. Makara, The influence of lead discovery strategies on the properties of drug candidates, Nat. Rev. Drug. Discov. 8 (2009), pp. 203–212. doi:10.1038/nrd2796.
   PubMed Web of Science ®Google Scholar
• X.M. Chen, T. Lu, S. Lu, H.F. Li, H.L. Yuan, T. Ran, H.C. Liu, and Y.D. Chen, Structure-based and shape-complemented pharmacophore modeling for the discovery of novel checkpoint kinase 1 inhibitors, J. Mol. Model. 16 (2010), pp. 1195–1204. doi:10.1007/s00894-009-0630-y.
   PubMed Web of Science ®Google Scholar
• W. Tai, T. Lu, H. Yuan, F. Wang, H. Liu, S. Lu, Y. Leng, W. Zhang, Y. Jiang, and Y. Chen, Pharmacophore modeling and virtual screening studies to identify new c-Met inhibitors, J. Mol. Model. 18 (2012), pp. 3087–3100. doi:10.1007/s00894-011-1328-5.
   PubMed Web of Science ®Google Scholar
• X. Liu, D. Shi, S. Zhou, H. Liu, H. Liu, and X. Yao, Molecular dynamics simulations and novel drug discovery, Expert. Opin. Drug. Discov. 13 (2018), pp. 23–37. doi:10.1080/17460441.2018.1403419.
   PubMed Web of Science ®Google Scholar